ADORA2A and cancer: Nevertheless, approval of the A2AR antagonist Istradefylline for the treatment of Parkinson’s Disease53 and several early phase clinical trials of the A2AR antagonist CPI-444 in cancer indicate that autoimmune side effects of A2AR blockade can be minimal.